With the peak of COVID-19 cases occurring between 3.5 to four weeks after controlled interventions were put into place in China, US researchers are urging the public to ramp up social distancing efforts and increase testing immediately.
A phase 1 trial evaluating an investigational vaccine designed to protect against COVID-19 has begun in Seattle. The study will enroll 45 healthy people aged 18 to 55, over approximately 6 weeks. The first participant received the investigational vaccine today. Adults in the Seattle area may join the study.
Study provides first potential targets for effective immune responses against COVID-19. The findings provide essential information for vaccine design against SARS-CoV-2.
